Gore and Associates: Grant/Research Support, Eurofins Transplant Genomics: Advisor, George Cholankeril: Nothing to Disclose, Deepak Gupta: Nothing to Disclose, Gene Im: KorroBio: Consultant, Echosens: Device support for research, Prasun Jalal: Nothing to Disclose, Janice Jou: Nothing to Disclose, Constantine Karvellas: Grifols: Advisor, Miromatrix: Data safety monitoring board for clinical trial, Saro Khemichian: Nothing to Disclose, Michael Kriss: Nothing to Disclose, Alexander Kuo: Nothing to Disclose, Ming Lin: Nothing to Disclose, Christina Lindenmeyer: Merck: Author for Merck Manuals, Robert Rahimi: Salix: Grant/Research Support, Mallinckrodt: Grant/Research Support, Kirti Shetty: Nothing to Disclose, Douglas Simonetto: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Lance Stein: Abbvie: Speaking and Teaching, Gilead: Speaking and Teaching, GSK: Consultant, Intercept: Speaking and Teaching, Intercept: Consultant, Madrigal: Speaking and Teaching, Ipsen: Speaking and Teaching, Ruben Hernaez: Nothing to Disclose, Brett Fortune: WL Gore and Associates: Consultant, BD Medical: Consultant, Manhal Izzy: Mallinckrodt: Speaking and Teaching 682 ALBUMIN REPROGRAMS THE B CELL TRANSCRIPTIONAL LANDSCAPE AND RESCUES NEUTROPHIL DYSFUNCTION IN IMMUNOCOMPROMISED PATIENTS WITH ADVANCED CIRRHOSIS Joan Claria 1 Ferran Aguilar 2 Juan-Jos Lozano 3 Laura Jimnez-Gracia 4 Juan Nieto 4 Berta Romero-Grimaldo 5 Xavier Marcos 6 Emmanuel Weiss 7 Jonel Trebicka 8 Inmaculada Hernndez 9 Javier Fernandez 1 Mireia Casulleras 1 Cristina Lpez-Vicario 5 Sinan Muldur 10 Alex Hopke 10 Alexandru Vlagea 1 Ana Aransay 11 Domenica Marchese 4 Mauro Bernardi 12 Rajiv Jalan 13 Paolo Angeli 14 Giuliana Magri 15 Andrea Cerutti 16 Daniel Irimia 10 Holger Heyn 4 Vicente Arroyo 17 Richard MOREAU 18 , 1 Hospital Clnic-IDIBAPS, 2 European Foundation for the Study of Chronic Liver Failure (EF CLIF), 3 CIBERehd, 4 CNAG, University of Barcelona, 5 Hospital Clnic-IDIBAPS, CIBERehd, 6 Translational Clinical Research Program, IMIM, 7 AP-HP, INSERM, Universit Paris-Cit, 8 University of Mnster, 9 CNAG, University of Barcelona, IRB, 10 Center for Engineering Medicine and Surgery, Massachusetts General Hospital, Harvard Medical School, 11 CIC bioGUNE, 12 University of Bologna, 13 University College London Medical School, 14 University of Padova, 15 University of Barcelona, 16 ICREA, Translational Clinical Research Program, IMIM, 17 European Foundation for the Study of Chronic Liver Failure, 18 European Foundation for the Study of Chronic Liver Failure, INSERM Background: Patients with acutely decompensated (AD) cirrhosis are immunocompromised and have higher predisposition to infections
Yang Y, Zheng M, Han F, et al
Forman JE, Timperley CM, Aas P, Abdollahi M, Alonso IP, Baulig A, Becker-Arnold R, Borrett V, Cario FA, Curty C, Gonzalez D, Kovarik Z, Martnez-lvarez R, Mikulak R, De Souza Nogueria E, Ramasami P, Raza SK, Saeed AEM, Takeuchi K, Tang C, Trifir F, van Straten FM, Waqar F, Zaitsev VN, Zina MS, Grolmusov K, Valente G, Payva M, Sun S, Yang A, Van Eerten D (2018) Innovative technologies for chemical security
In addition, data from studies of RSV infections in humans and in animal models revealed that this virus suppresses adaptive immune responses that could eliminate it from the respiratory tract
